Triple

T4784966
Position Surface form Disambiguated ID Type / Status
Subject mAb114 E106453 entity
Predicate hasFullName P16 FINISHED
Object ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
 E468967 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ansuvimab | Statement: [mAb114, hasFullName, ansuvimab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: ansuvimab
Context triple: [mAb114, hasFullName, ansuvimab]
  • A. Kymab
    Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
  • B. Leqembi
    Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
  • C. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • D. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • E. aflibercept
    Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: ansuvimab
Triple: [mAb114, hasFullName, ansuvimab]
Generated description
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: ansuvimab
Target entity description: Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
  • A. Kymab
    Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
  • B. Leqembi
    Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
  • C. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • D. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • E. aflibercept
    Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69bd43f4a9588190bf73e20bc27c03cc completed March 20, 2026, 12:56 p.m.
NER Named-entity recognition batch_69bd65ae49ec81908f16248d22d1155f completed March 20, 2026, 3:20 p.m.
NED1 Entity disambiguation (via context triple) batch_69be43dbdec88190817845e7930a18f6 completed March 21, 2026, 7:08 a.m.
NEDg Description generation batch_69be447c21d48190ab57c8761e733ff4 completed March 21, 2026, 7:10 a.m.
NED2 Entity disambiguation (via description) batch_69be45f5ebec8190b62c428b465d1bd9 completed March 21, 2026, 7:17 a.m.
Created at: March 20, 2026, 1:22 p.m.